Linkage Tool: Canadian Post COVID-19 Condition Research Network Funding Opportunity

To achieve the goals and objectives of the Canadian Post COVID-19 Condition Research Network through an expedited process, strong connections are essential. One of the ways CIHR is supporting the development of such connections is through this Linkage Tool. The table below provides information submitted by individuals and/or organizations interested in sharing information and/or establishing collaborations in relation to this funding opportunity.

Information is provided on a voluntary basis and in no way confers any advantages in the evaluation and/or funding of applications, nor does it replace or constitute a Registration to this Funding Opportunity.


The information is provided in the language in which it was submitted by the respondent.

Contact information Location Stakeholder/
Participant Type
Area(s) of Interest Additional Information
Daisy Fung Assistant Clinical Professor Dept of Family Medicine, University of Alberta Faculty of Medicine 7802973293 Alberta

Health Professional


Family physician and medical educator (medical students and residents) who worked in one of the largest Long Term Care covid outbreaks in Alberta and has an interest in this population and the chronic outcomes in those who survived, and advocacy going forward to protect them from future tragic outcomes. I am also a Long COVID ME patient myself, and open about my story and the bias experienced as a woman, physician, and chronic disease sufferer. I am not a formal researcher hence my post here, as I need the linkages to try become more involved. I am open to collaborating/partnering with others on an existing or new project in any form, as a patient or a family physician or both, in any capacity that moves us forward in dealing with covid, long covid, and vulnerable populations, especially women, the elderly, and Long Term Care patients.
Kelly McNagn
Professor of Biomedical Engineering and Medical Genetics
University of British Columbia
604 822 7824
British Columbia

Knowledge User

Independent Researcher

As Co-Leader of UBCs ImmunoTherapeutics Cluster, I am trying to reshape the way we approach research and disease. Our contention is that ALL disease has an immune component and that, with knowledge of the specific immune at play in each disease, we can modulate immune response to therapeutic benefit. With that in mind, our vision is to:
  1. create open access core technology hubs that facilitate discovery of immune components at play in any specific disease and design an appropriate, equitable therapeutic intervention (LNP/mRNA based, microbiome based, antibody or protein based, cell based, etc).
  2. Engage 5 pillar communities at the outset of each investigation/therapy development project: basic researchers, clinical researchers, biotech industry partners, health care economists/providers, patient support groups. We believe engaging these partners at the beginning of a project can shave years of the required time for developing an appropriate equitable intervention.

Areas of my personal interest:

  • The Immune System as a Central Player in All Disease
  • Integration of Cohort Study Data to Reveal Fine Details of Disease and Reveal Therapeutic Targets - Biomarkers of Human Disease
  • Immune Modulation and ImmunoEngineering for Improving Disease Outcomes
  • Design of Highly Accurate Animal Models of Human Disease
  • Innate Lymphoid Cells in Tissue Homeostasis and Inflammation
  • Therapeutic Targets for Cancer
  • Therapeutic Targets for Chronic Inflammatory Disease
Freimut Juengling
Professor, Director, Division of Oncologic Imaging
University of Alberta, Alberta

Independent Researcher

Health Professional

Molecular Imaging Biomarkers for post COVID-19 Condition: Functional Brain imaging correlates of long COVID in PET/MRI: resting state fMRI vs. FDG PET/ 15-O-Water-PET, quantitative metabolism, connectivity analysis; evidence for inflammatory brain disease (TSPO/activated microglia imaging). Correlation of quantitative brain imaging parameters with clinical indicators, neuropsychological scores and lab findings. To establish non-invasive imaging biomarker / quantitative imaging correlates for COVID-19 related or post-vaccine inflammatory cardiomyopathy / myocarditis in PET/MRI: ventricular function, late Gadolinium enhancement, quantitative 15-O-water perfusion and inflammation specific signal on CXCR4 PET imaging (= targeting T-Lymphocytes). Combined cardiac and brain imaging could provide insights on the heart-brain-axis. We can offer to perform longitudinal quantitative studies of brain metabolism, functional brain connectivity and inflammatory brain disease, as well as quantitative studies of heart function and inflammatory changes related to myocarditis in patients with post COVID-19 Condition or post-vaccine myocarditis. We do have the expertise, capacity, skill-set, motivation and infrastructure to collaboratively perform fully quantitative PET/MRI studies, if funding is granted within the network.
Date modified: